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ABSTRACT 
 
Ebola virus is a virulent pathogen that causes a highly lethal hemorrhagic fever in human and 
nonhuman species. It has a lethality rate of around 50-90%. Ebola Virus is a single stranded & 
negative RNA virus. It is a pathogen that belongs to Filoviridae family of RNA virus. Ebola is 
considered as a level-4 agent as it requires high range of biohazard containments for analysis 
and studies. The rapid growth of this virus infection has made the scenario so complicated to 
control this disease. Ebola virus is unreceptive to many anti-viral drugs or antibiotics also not 
a valid treatment is yet discovered for this disease caused by this virus. So there is an urgent 
need to explore the drug targets and discover novel anti-viral agent to fight against the virus. 
Proteins that used to help in pathogenesis of organism are selected as drug targets. Subsequent 
researches identified a cell surface receptor called TIM-1 for Ebola and Marburg viruses that 
typically enhances filovirus infection in many cells. Various function of TIM-1 in pathogenesis 
made it a potential drug target to control infection. Using bioinformatics based approach 
potential drug molecules are discovered against the target protein. The objective of the current 
study to explore a novel anit-viral agent that does act against TIM-1 receptor of Ebola virus 
using bioinformatics tools. Briefly, 25 inhibitors against TIM-1 protein were selected from 
literature. Both ligand and protein were optimized using Autodock Vina software.  TIM-1 was 
docked with those selected compounds and stability was estimated on the basis of total binding 
energy. Deslanoside, Vinorelbine, Digoxin were found to be most suitable agent that inhibit 
TIM-1. Further, drug likeness and ADMET properties were evaluated by using molinspiration 
& Pre-ADMET. These compounda can be taken for wet lab testing as anti-Ebola therapy. In-
silico docking analysis is done repeatedly to find the most suitable compound. 
Keywords: In silico, hemorrhagic fever, TIM-1, EBOV, Deslanoside , Venorelbine 
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1.INTRODUCTION 
 
EBOV is a deadly pathogen belonging to Filoviridae family of RNA virus which is single-
stranded and negative RNA virus. It typically cause hemorrhagic fever in human and non-
human species with mortality rate very high (50-90%). Hemorrhagic fever mainly leads to 
death and severe bleeding from different parts of the body [1]. It takes place in two phases, late 
phase & incubation period. The natural host of EBOV is still not known. The rapid growth of 
this virus infection has made the scenario so complicated to control EVD. The specific 
mechanism of the pathogenicity of EBOV has not been clearly discovered yet. No current anti-
viral drug or anti-viral therapy has been invented which could be effective against the infection. 
A high range of biohazard containments are required for research studies and analysis. EBOV 
is termed as a level 4 agent which alludes that it is extremely infective and lethal. 
                         EBOV was first seen in Africa in 1976 in the republic of Congo. Outbreaks 
have been appeared for past 3-4 years in central Africa. Outbreak in 2014 is one of the largest 
outbreaks in some places of West Africa [17]. Countries like Guinea and Sierra Leone have 
been severely attacked with the syndrome of Ebola Virus according to the report Centre for 
Disease Prevention and Control. But still there is no conventional therapeutics has been 
discovered to inhibit the infection of this deadly virus. Ebola infection has been increasing 
rapidly in an exponential way around the globe. From the statistical analysis it has been found 
that the lethality rate has reached to the extreme figure (83%). Though the virus source is still 
not known, the mode of transmission is well described [2]. The therapy to combat the infection 
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due to this virus has been a challenge. Drugs are very less available and limited. So some 
screening approach to find approved drugs which can be proposed as a potential anti-viral agent 
for the treatment of patients with EBOV infection. So mainly Ebola virus cause hemorrhagic 
fever as the virus separates the walls of the capillaries, which leads to leaking of blood from 
different parts of body. Basically hemorrhagic fever occurs due to 5 RNA virus family 
including Filoviridae family. So there is an urgent need to develop therapeutic domains. In 
silico methods have been adopted for screening of different compounds and to develop an anti-
viral agent to fight against several disease. Computer added drug design is one of the best 
bioinformatics approach to develop selected drug leads which can be proposed further for 
clinical analysis of different disease. These computer and computational methods involve 
protein structure to be docked with individual drug molecule. Further calculating the binding 
affinity scores, the best drug lead can be proposed. This study deals with docking of 25 inhibitor 
molecules for Ebola. Consequently a series of docking has been performed with the ligand and 
the drug target. Based on the dock score or binding energy values with some other properties, 
the potential drug leads have been obtained. The main aim of this study to contribute some 
effort for researches, those are being carried out in clinical section. So this hypothetical 
approach can be helpful for molecular therapeutic analysis and studies to get a detailed effect 
of therapy for healing the infection.[2] [4] 
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2.LITERATURE REVIEW 
2.1. EBOLA VIRUS: 
2.1.1.  Structure: 
Ebola Virus is a single stranded (ss) negative RNA virus which is in encapsulated form. This 
virus comes under the family of Filoviridae. It is having a highly filamentous structure. It looks 
like it has a thread like structure. It may be coiled or branched. EBOV is typically 800nm long 
and diameter of around 80nm. Each virion contains a nucleocapsid with in which a negative ss 
RNA is present. The genetic material RNA is covered by nucleoprotein (NP). Ebola has also a 
enzyme called Polymerase that helps for replication. Hence the RNA is surrounded by NP, 
Polymerase and four viral proteins (VP40, VP35, VP24, and VP30). The nucleocapsid is 
encapsulated by outer viral envelop. In between the matrix of nucleocapsid and viral envelop 
VP40 and VP24 are present.[4] [5] 
 
 
                             (Figure 2.1virion structure showing all its components) 
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                         EBOV genome is around 10kb length with seven ORF that encodes for all 
structural proteins like VP35, NP, VP30 and Polymerase. It also encodes for matrix associated 
protein (GP, VP40 and VP24). Like the Marburg virus, the Glycoprotein of EBOV gives two 
gene products, one is a protein of 60-70 kDa and other one is of 150-170 kDa. These get into 
membrane by Transcriptional editing.[4] [15] 
 
                                      Figure 2.2 Gene order of the virus genome 
 
Matrix Proteins: 
EBOV viral protein (matrix protein) VP40 does the shaping and regulates the process for the 
purpose of budding. In VP40, subunits are merged to get a hexamer structure for this viral 
protein. A linker which is flexible is in contact at the ending part of chain. Structural integrity 
has to be maintained inside the virion. There is an association of budding of virus and 
endocytosis. Another matrix protein VP24 has a role to lower down the production of 
interferon. The important thing is the correct combination of NP, VP35 and nucleocapsid. [3] 
 
Nucleocapsid: 
At the mid portion of the virus, the nucleocapsid is present. It has a role of protecting the 
genome. The RNA is wrapped by the Nucleoprotein (NP). It creates a complex structure which 
is helical mostly, but it is not rigid. So EBOV looks like a wave structure. As the EBOV enters 
in to the cell, the polymerase creates much more number of copies of genome.[18] [19] 
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Glycoprotein: 
Glycoprotein (GP) does the RNA editing and on cell surface protein is expressed like GP 
Spikes. These help to fuse the membrane of the viral particle into the cell. This is important for 
EBOV pathogenicity. [16]  
 
 
2.1.2. Ebola Virus Transmission: 
By direct interaction with bodily fluids such as blood, sweat, vomit, urine etc., it really cause 
to transmit the virus into human. It is one of the primary reason for outbreak of EBOV. Fruit 
Bats seemed to have this syndrome first. EBOV infection first appeared in different such as 
bat, monkey etc. To replicate in the animal cell with causing a high infection is the main aim 
or goal of Ebola virus. Ebola Virus contain GP and now the cell recognize the GP. The 
glycoprotein receptor on the cell surface get attached with the virus containing GP. This is the 
way Ebola virus enter the cell.  Once Ebola virus enters the cell, it will release its contents, the 
genetic material, nucleoprotein & polymerase. Thus the genetic material will be replicated and 
undergoes some few processes like transcription and translation, which will create other 
structure that that the virus requires. The virus basically hijack the cell and replicates within it. 
Once it replicates it’s all contents (genetic material, polymerase (L), nucleoprotein (NP)) will 
be packaged up again to create multiple Ebola virus. So the virus keeps replicating inside the 
bat cell. The bat cell is the optimal environment for Ebola virus replication. Now the infected 
fruit bat can transmit the Ebola virus to a human. Infection is by direct contact from blood or 
other bodily fluids.[4] [6] [8] 
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Incubation period: 
It is the time required from the infection with the virus to which a symptom occur which is in 
between 2-21 days. Different methods adopted for diagnosis of EBOV such as ELISA, antigen 
recognition analysis, PCR. 
 
2.2. DRUG TARGET FOR EBOV: 
2.2.1. TIM-1:  
         Proteins that used to help in pathogenesis of organism are selected as drug targets. 
Subsequent researches identified a cell surface receptor called TIM-1 for Ebola and 
Marburg viruses that typically enhances Filovirus infection in many cells. Various 
function of TIM-1 in pathogenesis made it a potential drug target to control infection. 
It is one cell surface protein or receptor which essentially bind to the GP of EBOV. The 
Igv domain of this receptor contain pdtser are crucial for EBOV entry. As the pdtser 
interacts with the envelope of virion, it helps to entry of the virus. Hence it causes the 
infection inside. Pdtser is basically a residue for binding purpose or in other way it is a 
binding residue of Igv. TIM-1 increases basically infection in many cells such as 
epithelial cells. Ebola virus GP direct interacts with it and spread infection. [9]  
                           Recently found TIM-1 (also having some other name: HAVCR-1, 
KIM-1) mainly expressed on epithelial cells, B cell, mast cell etc. It behaves as a 
receptor on the surface. The immunoglobulin (Igv) variable which is one type of 
domain, they are actually extended from PM. There is one another cell surface receptor 
called as niemann-pick (NPC1) which also seem to be required for EBOV entry into 
host cell. So both NPC1 and TIM-1 can be the potential drug target for an anti-ebola 
drug. But these NPC1 are not expressed in all type of cells. So mainly the Ebola 
infection is done by the other one i.e. TIM-1. Designing of one anti-viral drug that could 
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be able to restrict the virus entry into cells like epithelial cell. This anti-viral molecule 
somehow reduce the effect of the disease. TIM-1 essentially binds to virus GP and 
allows EBOV to enter to get infection in permissive cells. Researchers found this 
receptor which is the first cellular receptor for EBOV. It is the receptor which is 
identified first. So in this study, the drug target has been taken as TIM-1, which is to be 
docked with different drug molecules to design our anti-viral agent of interest. [11] 
 
                                 
           Figure 2.3 TIM-1 (in green) expressed on human cell, microscopic image 
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3.TOOLS REQUIRED FOR IN SILICO 
ANALYSIS 
 
3.1. PDB: 
                        PDB (Protein Data Bank) is one of the single and best database which 
keeps the record of all data of proteins, genes, biomolecules, and nucleic acids. It was first 
introduced in Brookhaven National Lab. in the year 1971. It keeps all the structural data and 
info. of biomolecule which are deduced from XRC as well as NMR technology. It can be freely 
used and can be accessed on the internet referring to the site www.pdb.org. 
3.2. PUBCHEM: 
                           This is the database which carries all chemical molecules and it also 
contains its activities opposing to the biological analysis. This database is regulated by NCBI 
which is a part of NLM. Consequently this has been maintained by NIH. It can be easily 
accessed in the internet and the structures of all macromolecule can be freely downloaded from 
the website. Other properties of molecules can be checked like MW, H-bond donor and 
acceptor and logP values etc.                           
3.3. AUTODOCK TOOLS: 
                 Autodock is a free software which can be used for the purpose of docking 
study. It can predict and measure the molecule like drug compounds which bind to the protein 
or receptor with 3D structure. So it is an automated tool for predicting the ligand and receptor 
interaction with showing different free affinity values. Different versions of these software are 
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available online, which can be freely downloaded from the site (www.autodock.scripps.edu). 
In the field of CADD for designing required drug compounds, it plays a vital role to help in 
developing many bioactive compounds. There are a lot of progress going on in XRC 
technology which allows main protein structures as well as nucleic acids also. These can be 
acted as agents for the control of different diseases that occurs in primates. The study of binding 
of such agents with potential target is crucial for development methods.  
3.4. CHEMSKETCH: 
                  Chemsketch is a software block from ACD, from which it can help biochemist 
and researchers to draw the chemical structures of different compounds, drawing schematic 
chemical diagrams, calculation of properties such as chemical property and developing analysis 
reports etc in a quick manner. 
ACD/ChemSketch follows some steps: 
 Mode is Structure so as to draw the structure in chemical form and to calculate different 
properties of molecule. 
 Mode is draw or text and processing in graphic way. 
 Modules that are additional can extend the possibilities of ACD/chemsketch. 
3.5. CASTP SERVER: 
                               CastP server is a bioinfo. tool used to carry out the prediction of active site 
of required protein. It also predicts geometric location of protein as well as delineation and 
measurement of surface areas of 3D structure of corresponding protein. Protein structures 
downloaded from PDB are also used here to find the pocket information, area of pocket, 
circumference and surface area of openings of the pocket. This server is regulated by Illinois 
University, Chicago. [12] 
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3.6. OPENBABEL: 
                             Openbabel is a free software which is used for the purpose of changing file 
format from one to another. It is a very easy and fast exchangeable tool as it takes very few 
time for conversion of the file format. In autodock tools it demands the file format of both 
protein and ligand in .pdb format, so mainly openbabel converts any format to .pdf format in a 
quick process.                        
3.7. PRE-ADMET: 
                              PreADMET is an application which is web-based and can be used for 
prediction of ADME readings. In silico method usually used to develop drug likeness record. 
PreADMET has a current version 2.0 which has four publications and it is available 
commercially. From PreADMET different properties can be calculated like drug likeness, 
ADME and analysis of toxicity. 
                                  
3.8. PYMOL: 
                        Pymol is a visualization software created by WL Delano and it is an 
open source tool. It creates high quality visualization of biomolecules with 3D structure. It is 
recently commercialized by Schrodinger.inc.It is vastly used in the field of computer based 
drug designing and structural biology. 
3.9. DISCOVERY STUDIO 4.1: 
             This is a visualization tool and have a vast application in molecular docking process 
for drug designing purpose. This software is very helpful for finding interacting residues during 
docking of ligand compounds with protein. [14] 
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4.1. Protein structure determination and sequence 
chain analysis: 
 
                   PDB ID of TIM-1 receptor is found to be 2OR8. Then the pdb website was 
accessed (www.pdb.org). Typed the PDB ID 2OR8 in search box, this got the result of 
sequence chain and checked the 3D view of the protein from PDB database on Jmol 
viewer. Then the Pdb file 2OR8 is downloaded and saved as .pdb format in the system. 
                . TIM-1 has a total of 2 chains. These chains are represented by unique 
entities of two sequences. Information mentioned below regarding the protein TIM-1 
are determined from PDB. 
                          
            Figure 4.1 3D view of tim-1, source:PDB, image is viewed under Jmol [10] 
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CHAIN A:  
This is the first chain (A). This light polymeric chain contains 47 residues. The 
secondary structure shown to be 5% helical with 2 helices and having 6 residues that 
contains 40% beta sheets and 11 strands. The secondary structure of this receptor 
protein is mentioned below: 
 
                 Figure 4.2 TIM-1 secondary structure, CHAIN A , Courtesy:PDB 
 
CHAIN B:  
This is the second chain (B). This polymeric chain contains 49 residues. The secondary 
structure shown to be 5% helical with 2 helices and having 6 residues that contains 42% 
beta sheets and 11 strands. The secondary structure of this receptor protein is mentioned 
below: 
 
             Figure 4.3 TIM-1 secondary structure, CHAIN B, Courtesy:PDB 
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4.2. Inhibitor identification and preparation of their 
structure: 
                          
                                  25 non-specific EBOV inhibitors were found out and listed. From the 
Nature Paper Journal, selection of 25 drug compounds was done. Downloading of 
corresponding chemical compound structure was done from PUBCHEM database. The files 
downloaded was in .sdf form. So Openbabel tool was used to change the format to .pdb file. A 
list of 25 selected inhibitor are listed below, those are to be docked with TIM-1 protein. 
TABLE 4.1 List of inhibitors 
1) AZACLORZINE 
 
Pubchem CID- 39526 
Molecular Weight – 413.96 g/mol 
Molecular Formula- C22H24 Cl1N3O5 
 
2) BIFEMELANE 
 
Pubchem CID- 2377 
Molecular Weight – 269.58 g/mol 
Molecular Formula- C18H23NO 
 
3) CEPHARANTHINE 
 
Pubchem CID- 10206 
Molecular Weight – 606.707 g/mol 
Molecular Formula- C37H38N2O6 
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4) NITROVIN 
 
Pubchem CID- 6252910 
Molecular Weight – 360.28 g/mol 
Molecular Formula- C19H12N6O6 
 
5) CYCLOMETHYCAINE 
 
Pubchem CID- 10839 
Molecular Weight – 359.50 g/mol 
Molecular Formula- C22H23NO3 
 
6) TILORONE 
 
Pubchem CID- 5475 
Molecular Weight – 410.54 g/mol 
Molecular Formula- C25H34 N2O3 
 
7) ALBENDAZOLE 
 
Pubchem CID- 2082 
Molecular Weight – 265.33 g/mol 
Molecular Formula- C12H15 N3O2 S 
 
8) ALVERINE CITRATE 
 
Pubchem CID- 21718 
Molecular Weight – 473.55 g/mol 
Molecular Formula- C26H35NO7 
 
9) AMODIAQUINE 
 
Pubchem CID- 2165 
Molecular Weight – 355.86 g/mol 
Molecular Formula- C20H22 Cl1N3O 
 
 20 
 
10) BENZOTROPINE MESYLATE 
 
Pubchem CID- 238053 
Molecular Weight – 463.54 g/mol 
Molecular Formula- C22H29 NO4 S 
 
11) BAZEDOXIFENE 
 
Pubchem CID- 154257 
Molecular Weight – 470.60g/mol 
Molecular Formula- C30H34 N2O3 
 
12) BITOLTEROL 
 
Pubchem CID- 35330 
Molecular Weight – 461.54g/mol 
Molecular Formula- C28H31 NO5 
 
 
13) VINORELBINE 
 
Pubchem CID- 60780 
Molecular Weight – 778.93g/mol 
Molecular Formula- C45H54N4O8 
 
14) VINCRISTINE 
 
Pubchem CID- 5978 
Molecular Weight – 824.95g/mol 
Molecular Formula- C46H56N4O10 
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15) TAMOXIFENE 
 
Pubchem CID- 2733526 
Molecular Weight – 371.54g/mol 
Molecular Formula- C26H29NO 
 
16) RALOXIFENE 
 
Pubchem CID- 5035 
Molecular Weight – 473.58g/mol 
Molecular Formula- C28H27NO4 
 
17) NOCODAZOLE 
 
Pubchem CID- 4122 
Molecular Weight – 301.32g/mol 
Molecular Formula- C14H11N3O3 S 
 
18) NILOTINIB 
 
Pubchem CID- 644241 
Molecular Weight – 529.515g/mol 
Molecular Formula- C28H22N7OF3 
 
19) TOPOTECAN 
 
Pubchem CID- 60700 
Molecular Weight – 421.44g/mol 
Molecular Formula- C23H23N3O5 
 
20) SPIRAMYCIN 
 
Pubchem CID- 6419898 
Molecular Weight – 843.05g/mol 
Molecular Formula- C43H74N2O4 
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21) MAPROTILINE 
 
Pubchem CID- 4011 
Molecular Weight – 277.40g/mol 
Molecular Formula- C20H23N 
 
22) DESLANOSIDE 
 
Pubchem CID- 28620 
Molecular Weight – 943.07g/mol 
Molecular Formula- C47H74 O19 
 
23) CLOMIPHENE 
 
Pubchem CID- 2800 
Molecular Weight – 405.95 g/mol 
Molecular Formula- C26H28 ClNO 
 
24) DIGOXIN 
 
Pubchem CID- 2724385 
Molecular Weight – 780.93g/mol 
Molecular Formula- C41H64 O14 
 
25) MEBENDAZOLE 
 
Pubchem CID- 4030 
Molecular Weight – 295.29g/mol 
Molecular Formula- C16H13N3O4 
 
4.3. Prediction of Active site : 
                            
                                                 Before docking the active site or the binding site of the protein 
was predicted. There are so much online tools and softwares are available to do the prediction 
of active site. CastP is one of the best software to evaluate the binding region or site in a protein. 
 23 
 
First of all, for active site calculation CastP requires the pdb file of the protein. As soon as the 
file has been uploaded or the PDB code is searched, it will give the all details about the active 
site. Then the result was viewed using several tools for purpose of visualization such as 
PYMOL, discovery studio etc. It gives the Cartesian X, Y, Z coordinates i.e. active site. These 
values will be used futher while docking experiments will start to happen in Autodock Vina. 
Grid Box prepation usually done prior to the docking step, so at that time it requires these 
coordinate values. 
4.4. Protein and ligand optimization :  
                                   Firstly the structure of the TIM-1 protein was acquired from the PDB 
site. Using the PDB ID (2OR8), the structure was downloaded and viewed in the Visualization 
tool PYMOL. Before performing the docking, some steps has been done known as 
minimization of energy or optimization step. In Vina, most PDB structures do not have 
hydrogen. So we need to add them using ADT. Structure has been minimized by adding polar 
hydrogen atom and removing water molecules. Further charges have been added such as 
kollman and gasteiger charge as for filling the missing loops. Now a charge field has been set 
up by adding polar hydrogen atoms and removing unwanted water. Again the ligands also 
downloaded from the PUBCHEM website and Drugbank library. The compounds downloaded 
are in sdf format and that has to be changed to pdb as this is prerequisite for ADT. 
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                                  Figure 4.4 screenshot during addition of hydrogen atom 
                                 
Total kollman charges added = 8.294 
 
 
                                Figure 4.5 screenshot while adding the kollman charge 
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Total gasteiger charge added = 0.998 
 
 
                            Figure 4.6 screenshot while adding the gesteiger charge 
 
 
4.5. Preparation of Grid Box: 
 
                                   A Grid Box has to be set up around the binding site or active site of the 
protein. It is a necessary step to perform molecular docking of ligand and receptor. By clicking 
on the grid option on the ADT interface, it will show a box for grid option. The coordinate 
values and the default parameters are entered. Number of points have been modified in X, Y, 
Z dimension by rotating the dial. The grid box should be large enough to accommodate the 
ligand in its extended conformation. As far as possibly it should not go into the empty space. 
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In Grid option box: 
Number of points in X-dimension = 94 
Number of points in Y-dimension = 40 
Number of points in Z-dimension = 50 
Centre Grid Box: 
X centre = -7.385 
Y centre = 17.199 
Z centre = -18.915 
After setting this parameter values spin option has been choosed and turned it ON. It will start 
spinning on the screen showing all parts of protein from all different angles whether it has 
covered the site properly or not. 
 
                                    Figure 4.7 screen shot during Grid Box Preparation 
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4.6. Docking using VINA : 
                          Docking is a method which evaluates the position of inhibitor 
compounds with the receptor for prediction of binding energy of complex or the affinity of 
ligands towards the protein. Docking analysis has been done with the help of Autodock Vina. 
Before that the optimization of protein and ligand was done. This two files were in .pdb format 
and placed in a folder named by the respective ligand. 25 compounds have been used, so 25 
folders have been created with giving the ligand names. Then the protein molecule was saved 
in .pdbqt format and so was for the ligand also. A conf.txt file also included in the folder. It has 
a certain format to give the input text. Now it was all set for docking. 
conf.txt File : 
receptor = protein.pdbqt                       
ligand = ligand.pdbqt 
 
center_x = -7.385    
center_y = 17.199 
center_z = 18.915 
 
size_x = 94 
size_y = 40 
size_z = 50  
out = result.pdbqt 
 
Command Prompt: 
For running the docking simulation and getting the binding affinity values certain commands 
were given. As the commands put properly in the command prompt affinity values will be 
coming for the respective ligand. 9 modes were evaluated and the first mode was taken as the 
best conformation of the compound in the binding site. 
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                 This same procedure was repeated for other compounds left for docking purpose. So 
a series of docking experiments was performed and value of least binding energy mode was 
noted down. Then log.txt file contains all the affinity scores of 9 conformations of the ligand. 
Result.pdbqt file was viewed using visualization tools like discovery studio and PYMOL.  
 
                         Figure 4.8 screenshot during performing docking with ADT 
4.7. Bioactivity & ADMET properties Evaluation: 
                                      
 Docking was performed and three binding complex having minimum energy will be 
essentially separated. The Bioactivity, physiochemical properties were checked from the 
website of molinspiration[11]. It gave all the results with showing properties of respective lead 
compounds. ADMET properties calculated from Pre-ADMET server. From this the best ligand 
compound was chose.  
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5.RESULTS & DISCUSSION 
 
5.1. Minimization of Protein : 
 
                       Before Docking the PDB structure of protein TIM-1 was downloaded from the 
website (PDB ID- 2OR8).  Minimization of Protein was done by adding polar H-atoms and 
removing water molecules which are not wanted. The process follows by addition of Hydrogen 
and removal of water parts for better binding.  
Total kollman charges added = 8.294 
Total kollman charges added = 0.998 
 
 
  
                Figure 5.1 Protein before minimization and after minimization  
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5.2. Docking Results:  
After Docking of 25 compounds, 9 orientaion values or modes were generated for 
each ligands. The first mode or conformation was considered as the best binding 
residue. The value of the first mode was noted down for that ligand. Thus a series 
of docking was performed so as to get the corresponding binding affinity scores. 
Binding complex of ligand with receptor was shown in PYMOL and DS 4.1.  
5.2.1. Docked complex structures: 
                 
 
(1)                                                                         (2)  
                                 
(3)                                                                         (4) 
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                  (5)                                                 (6)                                            (7) 
       
                   (10)                                                   (11)                                   (12) 
         
                 (13)                                                (14)                                          (15) 
          
                (16)                                                (17)                                             (18) 
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                (19)                                                   (20)                                         (21) 
 
       
                  (22)                                                    (23)                                         (24) 
 
                     (25) 
                       Figure 5.2 Docked complex of all ligands (1-25) 
 
5. 2.2.  Binding Energy Values of the ligands: 
Table 5.1 Affinity value of all ligands 
 
Ligands 
 
Affinity value 
(kcal/mol) 
Azaclorzine -9.8 
Bifemelane -6.6 
Cepharanthine -13.3 
Nitrovin -7.3 
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Tilorone -7.4 
Albendazole -6.5 
Alverine Citrate -8.3 
Amodiaquine -7.3 
Benzotropine mesylate -4.2 
Bazedoxifene -10.7 
Bitolterol -8.7 
Vinorelbine -15.9 
Vincristine -14.3 
Tamoxifene -8.7 
Raloxifene -11.2 
Nacodazole -8.0 
Nilotinib -11.9 
Topotecan -10.1 
Spiramycine -12.8 
Maprotiline -7.9 
Deslanoside -16.7 
clomifene -9.0 
Digoxin -15.7 
Mebendazole -8.0 
 
 
             
                  From the above table, it is shown that Deslanoside, Vinorelbine and Digoxin having 
the least binding energy value and forming the most stable docking complex with the protein 
in the active site. These compound have the better binding affinity compared to others. Among 
these three, Deslanoside has the highest dock score of -16.7 kcal/mol so this is having the best 
interaction among all the compounds docked with the protein. Likewise Vinorelbine acquires 
a dock score of -15.9 kcal/mol which is better affinity value in comparison to Digoxin. The 
binding complex of these ligands with the protein visualized in Disocvery Stusio version 4.1. 
It shows all 9 interacting residues of the ligands within the binding site. The properties of these 
ligands also checked using molinspiration and Pre-ADMET. Below a binding energy plot has 
delineated. 
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                                 Figure 5.3 Binding Energy plot of all ligands 
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(Deslanoside)                           (vinorelbine)                            (digoxin) 
                Figure 5.4 binding complex with residues using Discovery Studio 
Table 5.2 ligands with interacting residue name 
 
Ligand 
 
 
Affinity 
(kcal/mol) 
 
Interacting Residues 
DESLANOSIDE -16.7 LYS8,VAL7,GLU6,VAL5,HOH247,PRO18,VAL103, 
TYR4,HOH130 
VENORELBINE -15.9 VAL5,VAL103,PRO18,HOH158,GLN101,THR20,CY
S19,VAL103,LYS102 
DIGOXIN -15.7 PRO18,VAL5,HOH158,VAL103,LYS102,VAL103,L
YS102,GLN101, THR20 
 
5.3. Bioactivity and physiochemical properties: 
 
Table 5.3 Bioactivity and physiochemical Properties                
Properties Deslanoside Vinorelbine Digoxin 
LogP -0.808 5.918 1.117 
TPSA 282.229 133.882 203.077 
Rotatable Bonds 10 10 7 
GPCR ligand -3.26 -1.31 -1.28 
Kinase inhibitor -3.91 -2.55 -2.17 
Ion ch. modulator 3.82 -2.67 -2.39 
Protease inhibitor -2.89 -1.20 -0.88 
Nuclear receptor -3.71 -2.39 -1.88 
Enzyme inhibitor -3.09 -2.00 -1.26 
nON 19 12 14 
nOHNH 9 2 6 
IC50(μM) 0.485 0.066 0.763 
IC90 (μM) 11.7 0.190 3.45 
Max Inh.(%) 66 90 68 
CytotoxicityIC50(μM) 250 250 >500 
SelectivityIndex(fold) 515 >7546 327 
MOA Na+-K+ pump 
inhibitor 
Microtubule 
Inhibitor 
Na+-K+ pump 
Inhibitor 
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ADMET Prediction: 
Deslanoside:  
 (a) 
Digoxin: 
 (b) 
Venorelbine: 
 (c) 
Figure 5.5 ADMET properties of (a) Deslanoside (b) Digoxin (c) Venorelbine 
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6.CONCLUSION 
The current study focused on molecular docking analysis of 25 potential inhibitors of Ebola 
virus with the TIM-1 receptor. The main goal was to propose the most favourable ligand 
compound that could be effective to target the protein i.e. TIM-1. From the result it was 
determined that Deslanoside, Vinorelbine and Digoxin formed stable complex compared to 
other compounds.  These compounds showed maximum binding affinity to the receptor. These 
could be the best compounds to inhibit the Ebola entry into the host cell. Deslanoside and 
digoxin have a function to inhibit Na+-K+ pump as well as from the determined ADMET 
properties these can be accepted as potential therapeutic for Ebola infection. More in vivo study 
is required to analyse the mechanism of this virus and interaction mechanism of the compounds 
which are shown in this study. So the main aim is to narrow down the efforts of researchers in 
clinical laboratories by proposing these compounds for wet lab study which may lead to 
identify the novel anti-viral agent to inhibit Ebola infection. 
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